These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25686851)

  • 41. Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A
    Falsini M; Catarzi D; Varano F; Dal Ben D; Marucci G; Buccioni M; Volpini R; Di Cesare Mannelli L; Ghelardini C; Colotta V
    Bioorg Chem; 2019 Jun; 87():380-394. PubMed ID: 30913470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists.
    Karl MO; Peterson-Yantorno K; Civan MM
    Exp Eye Res; 2007 Jan; 84(1):126-34. PubMed ID: 17070802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.
    Catarzi D; Colotta V; Varano F; Poli D; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
    Bioorg Med Chem; 2013 Jan; 21(1):283-94. PubMed ID: 23171656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenosine receptor antagonists: Recent advances and therapeutic perspective.
    Saini A; Patel R; Gaba S; Singh G; Gupta GD; Monga V
    Eur J Med Chem; 2022 Jan; 227():113907. PubMed ID: 34695776
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.
    Jung KY; Kim SK; Gao ZG; Gross AS; Melman N; Jacobson KA; Kim YC
    Bioorg Med Chem; 2004 Feb; 12(3):613-23. PubMed ID: 14738972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based virtual screening discovers potent and selective adenosine A
    Matricon P; Nguyen AT; Vo DD; Baltos JA; Jaiteh M; Luttens A; Kampen S; Christopoulos A; Kihlberg J; May LT; Carlsson J
    Eur J Med Chem; 2023 Sep; 257():115419. PubMed ID: 37301076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2-Aryladenine derivatives as a potent scaffold for A
    Areias F; Correia C; Rocha A; Brea J; Castro M; Loza MI; Proença MF; Carvalho MA
    Bioorg Med Chem; 2019 Aug; 27(16):3551-3558. PubMed ID: 31280999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expeditious synthesis and biological evaluation of new C-6 1,2,3-triazole adenosine derivatives A1 receptor antagonists or agonists.
    Mathew SC; By Y; Berthault A; Virolleaud MA; Carrega L; Chouraqui G; Commeiras L; Condo J; Attolini M; Gaudel-Siri A; Ruf J; Rodriguez J; Parrain JL; Guieu R
    Org Biomol Chem; 2010 Sep; 8(17):3874-81. PubMed ID: 20617271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.
    Moro S; van Rhee AM; Sanders LH; Jacobson KA
    J Med Chem; 1998 Jan; 41(1):46-52. PubMed ID: 9438021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Taxicab geometry quantification system to evaluate the performance of in silico methods: a case study on adenosine receptors ligands.
    Kuder KJ; Michalik I; Kieć-Kononowicz K; Kolb P
    J Comput Aided Mol Des; 2020 Jun; 34(6):697-707. PubMed ID: 32112287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.
    Giovannoni MP; Vergelli C; Cilibrizzi A; Crocetti L; Biancalani C; Graziano A; Dal Piaz V; Loza MI; Cadavid MI; Díaz JL; Gavaldà A
    Bioorg Med Chem; 2010 Nov; 18(22):7890-9. PubMed ID: 20937560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives.
    Areias F; Correia C; Rocha A; Teixeira S; Castro M; Brea J; Hu H; Carlsson J; Loza MI; Proença MF; Carvalho MA
    Molecules; 2024 May; 29(11):. PubMed ID: 38893418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. De novo analysis of receptor binding affinity data of 8-ethenyl-xanthine antagonists to adenosine A1 and A2a receptors.
    Dalpiaz A; Gessi S; Varani K; Borea PA
    Arzneimittelforschung; 1997 May; 47(5):591-4. PubMed ID: 9205770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure-Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations.
    Stampelou M; Suchankova A; Tzortzini E; Dhingra L; Barkan K; Lougiakis N; Marakos P; Pouli N; Ladds G; Kolocouris A
    J Med Chem; 2022 Oct; 65(19):13305-13327. PubMed ID: 36173355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. N-[9-(ortho-fluorobenzyl)-2-phenyl-8-azapurin-6-yl]-amides as potent and selective ligands for A₁ adenosine receptors.
    Borghini A; Pietra D; Leonardi M; Giorgi I; Bianucci AM
    Chem Biol Drug Des; 2013 Jul; 82(1):22-38. PubMed ID: 23480235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structures of Human A
    Cheng RKY; Segala E; Robertson N; Deflorian F; Doré AS; Errey JC; Fiez-Vandal C; Marshall FH; Cooke RM
    Structure; 2017 Aug; 25(8):1275-1285.e4. PubMed ID: 28712806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
    van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; IJzerman AP
    J Med Chem; 1998 Oct; 41(21):3987-93. PubMed ID: 9767636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
    Squarcialupi L; Falsini M; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Dal Ben D; Lambertucci C; Volpini R; Colotta V
    Bioorg Med Chem; 2016 Jun; 24(12):2794-808. PubMed ID: 27161878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
    Ciancetta A; Cuzzolin A; Moro S
    J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities.
    Klotz KN; Kachler S; Lambertucci C; Vittori S; Volpini R; Cristalli G
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):629-34. PubMed ID: 12734636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.